Joseph L. Woolley

760 total citations
26 papers, 627 citations indexed

About

Joseph L. Woolley is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Joseph L. Woolley has authored 26 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 7 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Joseph L. Woolley's work include Pneumocystis jirovecii pneumonia detection and treatment (6 papers), HIV/AIDS drug development and treatment (6 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). Joseph L. Woolley is often cited by papers focused on Pneumocystis jirovecii pneumonia detection and treatment (6 papers), HIV/AIDS drug development and treatment (6 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). Joseph L. Woolley collaborates with scholars based in United States and United Kingdom. Joseph L. Woolley's co-authors include Kenneth R. Brouwer, Joseph W. Polli, Carl W. Sigel, Scott D. Studenberg, Joan E. Humphreys, Cosette J. Serabjit‐Singh, Stephen A. Wring, Liyue Huang, Charles A. Nichol and D. Clive and has published in prestigious journals such as The Journal of Infectious Diseases, Antimicrobial Agents and Chemotherapy and Stem Cells.

In The Last Decade

Joseph L. Woolley

25 papers receiving 600 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph L. Woolley United States 14 233 215 150 103 103 26 627
F A deLuna United States 15 218 0.9× 292 1.4× 85 0.6× 164 1.6× 23 0.2× 24 844
P. Hsyu United States 8 160 0.7× 110 0.5× 80 0.5× 88 0.9× 48 0.5× 15 479
Britt Jansson Sweden 14 80 0.3× 170 0.8× 89 0.6× 118 1.1× 91 0.9× 18 804
Angus N. R. Nedderman United Kingdom 14 376 1.6× 105 0.5× 45 0.3× 228 2.2× 143 1.4× 20 843
Anura L. Jayewardene United States 14 353 1.5× 58 0.3× 70 0.5× 114 1.1× 257 2.5× 23 628
Boris Zanolari Switzerland 13 183 0.8× 89 0.4× 45 0.3× 151 1.5× 47 0.5× 14 696
Paul Savina United States 14 525 2.3× 123 0.6× 144 1.0× 184 1.8× 292 2.8× 22 742
Eri Kanaoka Japan 11 182 0.8× 91 0.4× 79 0.5× 173 1.7× 85 0.8× 15 693
Pierre Comby France 9 292 1.3× 71 0.3× 43 0.3× 69 0.7× 84 0.8× 12 525
Alessandro Schipani United Kingdom 14 306 1.3× 115 0.5× 85 0.6× 346 3.4× 126 1.2× 19 948

Countries citing papers authored by Joseph L. Woolley

Since Specialization
Citations

This map shows the geographic impact of Joseph L. Woolley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph L. Woolley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph L. Woolley more than expected).

Fields of papers citing papers by Joseph L. Woolley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph L. Woolley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph L. Woolley. The network helps show where Joseph L. Woolley may publish in the future.

Co-authorship network of co-authors of Joseph L. Woolley

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph L. Woolley. A scholar is included among the top collaborators of Joseph L. Woolley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph L. Woolley. Joseph L. Woolley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Woolley, Joseph L., et al.. (2021). COVID‐19 in a Pediatric Patient. JPGN Reports. 2(2). e068–e068.
2.
Sadler, Brian M., Gregory E. Chittick, Ronald E. Polk, et al.. (2001). Metabolic Disposition and Pharmacokinetics of [14C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects. The Journal of Clinical Pharmacology. 41(4). 386–396. 16 indexed citations
3.
Huang, Liyue, Stephen A. Wring, Joseph L. Woolley, et al.. (2001). Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.. PubMed. 29(5). 754–60. 118 indexed citations
4.
Polli, Joseph W., et al.. (1999). Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor. Pharmaceutical Research. 16(8). 1206–1212. 185 indexed citations
5.
6.
Pudney, Mary, et al.. (1999). Atovaquone and Proguanil Hydrochloride: A Review of Nonclinical Studies. Journal of Travel Medicine. 6(S1). S8–S12. 22 indexed citations
7.
Hughes, Walter T., Elaine M. Sillos, Stephen W. LaFon, et al.. (1998). Effects of Aerosolized Synthetic Surfactant, Atovaquone, and the Combination of These on Murine Pneumocystis carinii Pneumonia. The Journal of Infectious Diseases. 177(4). 1046–1056. 12 indexed citations
8.
Studenberg, Scott D., et al.. (1997). THE PHARMACOKINETICS OF 1954U89, 1, 3-DIAMINO-7-(1-ETHYLPROPYL)-8-METHYL-7H-PYRROLO-(3, 2-f )QUINAZOLINE, IN DOGS AND RATS AFTER INTRAVENOUS AND ORAL ADMINISTRATION. Biopharmaceutics & Drug Disposition. 18(5). 433–442. 2 indexed citations
9.
Studenberg, Scott D., et al.. (1995). A robotics-based liquid chromatographic assay for the measurement of atovaquone in plasma. Journal of Pharmaceutical and Biomedical Analysis. 13(11). 1383–1393. 19 indexed citations
10.
Woolley, Joseph L., et al.. (1994). High-performance liquid chromatographic assay for the measurement of atovaquone in plasma. Journal of Chromatography B Biomedical Sciences and Applications. 652(2). 211–219. 25 indexed citations
11.
Woolley, Joseph L., et al.. (1991). The disposition and metabolism of [14C]piritrexim in rats after intravenous and oral administration.. Drug Metabolism and Disposition. 19(3). 600–608. 1 indexed citations
12.
Patel, Darshana, et al.. (1991). Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat.. Drug Metabolism and Disposition. 19(2). 491–497. 7 indexed citations
13.
Woolley, Joseph L., et al.. (1991). The disposition and metabolism of [14C]piritrexim in dogs after intravenous and oral administration.. Drug Metabolism and Disposition. 19(6). 1139–1146. 2 indexed citations
14.
Woolley, Joseph L., et al.. (1990). High-Performance Liquid Chromatographic Assay for the Simultaneous Measurement of Trimethoprim and Sulfamethoxazole in Plasma or Urine. Therapeutic Drug Monitoring. 12(4). 382–392. 24 indexed citations
15.
Weiss, Geoffrey R., Gisele Sarosy, Todd D. Shenkenberg, et al.. (1989). A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U). European Journal of Cancer and Clinical Oncology. 25(12). 1867–1873. 8 indexed citations
16.
Woolley, Joseph L., et al.. (1989). Competitive Protein Binding Assay for Piritrexim. Journal of Pharmaceutical Sciences. 78(9). 749–752. 3 indexed citations
17.
Woolley, Joseph L., et al.. (1987). Methapyrilene is a genotoxic carcinogen: Studies on methapyrilene and pyrilamine in the L5178Y/TK+/− mouse lymphoma assay. Mutation Research/Genetic Toxicology. 189(3). 285–297. 40 indexed citations
18.
Woolley, Joseph L. & Carl W. Sigel. (1982). Development of pharmacokinetic models for sulfonamides in food animals: Metabolic depletion profile of sulfadiazine in the calf. American Journal of Veterinary Research. 43(5). 768–774. 2 indexed citations
19.
Sigel, Carl W., et al.. (1981). Pharmacokinetics of Trimethoprim and Sulfadiazine in the Dog: Urine Concentrations After Oral Administration. American Journal of Veterinary Research. 42(6). 996–1001. 18 indexed citations
20.
Sigel, Carl W., Joseph L. Woolley, & Charles A. Nichol. (1975). Specific TLC Tissue Residue Determination of Sulfadiazine following Fluorescamine Derivatization. Journal of Pharmaceutical Sciences. 64(6). 973–976. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F A deLuna Breakdown of academic impact, for papers by P. Hsyu Breakdown of academic impact, for papers by Britt Jansson Breakdown of academic impact, for papers by Angus N. R. Nedderman Breakdown of academic impact, for papers by Anura L. Jayewardene Breakdown of academic impact, for papers by Boris Zanolari Breakdown of academic impact, for papers by Paul Savina Breakdown of academic impact, for papers by Eri Kanaoka Breakdown of academic impact, for papers by Pierre Comby Breakdown of academic impact, for papers by Alessandro Schipani
Rankless by CCL
2026